The role of small intestinal bacterial overgrowth in obesity and its related diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
PubMed 37044299 · doi:10.1016/j.bcp.2023.115546
What was done
This narrative review summarizes published literature on the relationship between small intestinal bacterial overgrowth (SIBO) and obesity, along with associated metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), and insulin resistance. The authors discuss putative underlying mechanisms and potential therapeutic interventions.
What was found
The abstract provides no quantitative data or effect estimates. It reports that SIBO is associated with obesity-related pathology and that proposed mechanisms involve loss of intestinal barrier integrity, increased gut permeability, elevated endotoxin levels, activation of inflammatory cascades, and bacterial translocation from the colon to the small intestine.
Why it matters
It highlights SIBO and intestinal dysbiosis as potential mechanistic contributors and therapeutic targets in the management of obesity and metabolic syndrome.
Limits
As a narrative review, it introduces no new primary data and lacks systematic search criteria. The abstract explicitly notes that causal relationships between SIBO and obesity remain unproven and that precise mechanisms have not yet been elucidated.
Cited by
- contradicts Small intestinal bacterial overgrowth (SIBO) directly induces type 2 diabetes and metabolic dysfunction.